Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Geyer

Showing results (261-270 of 278) with videos related to

Pageof 28
Sort By:
Leukemia Research|July 31, 2007
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemiaRebekah L Browning, Susan M Geyer, Amy J Johnson, et al.
Blood|November 15, 2008
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximabFarrukh T Awan, Neil E Kay, Melanie E Davis, et al.
Leukemia & Lymphoma|November 30, 2012
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulinJeremy T Larsen, William J Hogan, Ivana N Micallef, et al.
American Journal of Clinical Pathology|August 8, 2022
Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined SignificanceDragan Jevremovic, Ahmad Nanaa, Susan M Geyer, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaAnne M Noonan, Matthew R Farren, Susan M Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
Contemporary Clinical Trials Communications|May 29, 2026
Protocol for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiationUgur Sener, Bryan Neth, Taylor Galloway, et al.
American Journal of Hematology|March 10, 2025
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom MacroglobulinemiaJonas Paludo, Jithma P Abeykoon, Nirosha D Perera, et al.
Pageof 28

Showing results (261-270 of 278) with videos related to

Sort By:
Pageof 28
Leukemia Research|July 31, 2007
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemiaRebekah L Browning, Susan M Geyer, Amy J Johnson, et al.
Blood|November 15, 2008
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximabFarrukh T Awan, Neil E Kay, Melanie E Davis, et al.
Leukemia & Lymphoma|November 30, 2012
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulinJeremy T Larsen, William J Hogan, Ivana N Micallef, et al.
American Journal of Clinical Pathology|August 8, 2022
Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined SignificanceDragan Jevremovic, Ahmad Nanaa, Susan M Geyer, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaAnne M Noonan, Matthew R Farren, Susan M Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
Contemporary Clinical Trials Communications|May 29, 2026
Protocol for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiationUgur Sener, Bryan Neth, Taylor Galloway, et al.
American Journal of Hematology|March 10, 2025
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom MacroglobulinemiaJonas Paludo, Jithma P Abeykoon, Nirosha D Perera, et al.
Pageof 28